Oxidative Stress and Inflammatory Biomarkers in Gaucher Disease

Korábbi kezelés

• Concurrent disease; medical condition; or an extenuating circumstance that, in the opinion of the investigator, might compromise subject safety, study compliance, completion of the study, or the integrity of the data collected for the study.

Más betegség

• Medically unstable conditions in any group as determined by the investigators
• History of asthma that is presently being treated

Életkor

• Females who are pregnant or lactating or of child-bearing age who are not using acceptable forms of contraception

Egyéb

• Subjects who cannot or are unwilling to have blood drawn
• Unable to adhere to study protocol for whatever reason

• All participants must be 18 years or older.
• All enrollees must understand and cooperate with requirements of the study in the opinion of the investigators and must be able to provide written informed consent.
• Individuals with Gaucher disease who are medically stable for participation in study in the opinion of the investigator.
• GD subjects must be stable on a specific ERT and/or SRT therapy at a specific dose (for e.g. on a units/kg basis) for at least 2 years or be naïve to these therapies (no therapy for 2 years).
• GD1 patients, who have had a change in therapy i.e. a change in dose or switch from one drug to another, can be enrolled after at least 6 months have elapsed since the change and is considered stable in the opinion of the clinician providing care to the patient.
• All participants must not have taken antioxidants coenzyme Q-10, vitamin C, or vitamin E for 3 weeks prior to the study.